Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal.
Basilea Pharmaceutica is developing BAL-8557, a water-soluble prodrug of the triazole BAL-4815, for the potential treatment of fungal infections. By August 2005, a phase II study in oral candidiasis was underway. In September 2005, phase III trials were planned for invasive Candida and mold infections, including aspergillus and zygomycetes.
Odds
Frank C
FC
Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK. f.odds@abdn.ac.uk
D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001228:Aspergillosis / Q000188:drug therapy; D001230:Aspergillus / Q000187:drug effects; D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D009570:Nitriles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D014230:Triazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*
D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C508735:isavuconazole